Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 907-237-7 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Intreleven aldehyde is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route. The final absorption values derived for oral, dermal and inhalation are 50, 50 and 100% absorption. This information does not need to be used for route to route extrapolation because ‘no hazards are identified’ via the oral route and therefore no hazards are expected for the dermal and inhalation route. Intreleven aldehyde as such is lipophilic and may accumulate in the body fat.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
Toxicokinetic behaviour of Intreleven aldehyde
Introduction
The toxicokinetic behaviour of Intreleven aldehyde (generic CAS no.58296-81-4) is assessed to the extent that can be derived from the relevant available information, as is required at Annex VIII level according to the REACH requirements.
Intreleven aldehyde is a multi-constituent substance. It consists of the following main constituents: Undec-10-enal, (9E, 9Z) Undec-9-enal and (8E, 8Z) Undec-8-enal, and (7E, 8Z) Undec-7-enal. These constituents are aldehydes with a linear carbon backbone and contain one C=C double bond at various positions ranging from C7 to 10. Intreleven aldehyde is a liquid with a molecular weight of 168.28 that does not preclude absorption. The substance has a volatility of 6.0 Pa at 24°C, water solubility of 26.1 mg/L and a Log Kow of 4.47.
Absorption
Oral: Intreleven aldehyde is a liquid and has a relatively low molecular weight (168.28), moderate water solubility (26.1mg/L) and a log Kow of 4.47, all favouring gastrointestinal absorption. According to Martinez and Amidon (2002) the optimal log Kow for oral absorption falls within a range of 2-7. This shows that the substance is likely to be fully absorbed orally and at least in > 50%.
Skin: Intreleven aldehyde is a liquid and its physico-chemical properties allow dermal absorption: its molecular weight (168.28), log Kow (4.47) and water solubility (26.1 mg/L). The optimal molecular weight and log Kow for dermal absorption is <100 and in the range of 1-4, respectively (ECHA guidance, 7.12, Table R.7.12-3). The log Kow of the substance is above 4, therefore the rate of penetration may be limited by the rate of transfer between the stratum corneum and the epidermis, but uptake into the stratum corneum will be high. Based on these characteristics dermal absorption will not exceed oral absorption.
Lungs: For Intreleven aldehyde, the volatility (6.0Pa) indicates that the substance may be available for inhalation and absorption via inhalation as a vapour. The log Kow (4.47) indicates that the substance is moderately lipophilic and can be absorbed in the lung via diffusion but also via micellar solubilisation (ECHA guidance, 7.12, Table R.7.12-1). The blood/air (B/A) partition coefficient is another partition coefficient indicating lung absorption. Buist et al. 2012 have developed B/A portioning model for humans using the most important and readily available parameters:
Log PBA = 6.96 – 1.04 (Log VP) – 0.533 (Log Kow) – 0.00495 MW.
For Intreleven aldehyde the B/A partition coefficient would result in:
Log P (BA) = 6.96 – 1.04 x 1.42 – 0.533 x 4.47 – 0.00495 x 168.28 = 2.27.
This means that Intreleven aldehyde has a tendency to go from air into the blood. It should, however, be noted that this regression line is only valid for substances which have a vapour pressure > 100 Pa. Despite Intreleven aldehyde being out of the applicability domain and the exact B/A portioning may not be fully correct, it indicates that the substance will be readily absorbed via the inhalation route and an inhalation absorption of 100% can be used.
Metabolism
There are no experimental data on the metabolism of the substance. The theoretical Phase 1 metabolism is presented in Figure 1 in the attached file as predicted by the OECD Toolbox (3.3.5.17). This means that these aldehydes can oxidise into carboxylic acids which are processed in the mitochondrion resulting finally in CO2and H2O. This pathway is also mentioned in Annex III of The EFSA Journal (2008) 616-75. The final metabolite could be processed further as an unsaturated fatty acid, or it will be detoxified through phase II metabolic pathways such as glucuronidation.
Fig. 1 For Intreleven aldehyde auto-oxidation of the aldehyde group is expected. Oxidation to a carboxylic acid would yield a C11 fatty acid, which is processed in the mitochondrion resulting finally in CO2 and H2O. The final metabolite could be processed further as an unsaturated fatty acid, or it will be detoxified through phase II metabolic pathways such as glucuronidation.
Distribution
Based on the water solubility of the test substance (26.1mg/L), it may partly diffuse through aqueous channels and pores. However, the log Kow (4.47) would suggest that the substance would pass through the biological cell membrane. It is likely to distribute into cells and the intracellular concentration may be higher than extracellular concentration particularly in fatty tissues.
Excretion
Intreleven aldehyde is expected to be fully consumed in the mitochondria but excretion via the kidney may occur when metabolic pathway is overloaded. The physico-chemical properties of this substance, such as low molecular weight (<300) and moderate water solubility would enable renal excretion.
Bioaccumulation: Intreleven aldehyde as such is lipophilic and may accumulate in the body fat.
Conclusion
Intreleven aldehyde is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route. The final absorption values derived for oral, dermal and inhalation are 50, 50 and 100% absorption. This information does not need to be used for route to route extrapolation because ‘no hazards are identified’ via the oral route and therefore no hazards are expected for the dermal and inhalation route.
References
- Buist, H.E., Wit-Bos de, L., Bouwman, T., Vaes, W.H.J., 2012, Predicting blood:air partition coefficient using basic physico-chemical properties, Regul. Toxicol. Pharmacol., 62, 23-28.
- Martinez, M.N., And Amidon, G.L., 2002, Mechanistic approach to understanding the factors affecting drug absorption: a review of fundament, J. Clinical Pharmacol., 42, 620-643.
- Scientific Opinion of the Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with Food (AFC) on a request from the Commission Flavouring Group Evaluation 6, Revision 1 (FGE.06Rev 1): Flavouring Group Evaluation 6, Revision 1 (FGE.06Rev1): Straight- and branched-chain aliphatic unsaturated primary alcohols, aldehydes, carboxylic acids, and esters from chemical groups 1 and 4 (Commission Regulation (EC) No 1565/2000 of 18 July 2000). The EFSA Journal 616, 1-74.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.